Back

Inventage Lab shares surge 6.29% after U.S. patent approval for IVL3004

Verifying
  • Inventage Lab received final U.S. patent registration for its IVL3004 injectable treatment.
  • Inventage Lab shares rose 1,600 won, or 6.29%, to 27,050 won at 9:59 a.m.
  • Inventage Lab was selected for Global TIPS and plans Phase 2 preparation through 2030.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.